Trial Profile
Randomized Treatment Interruption of Natalizumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2020
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary) ; Glatiramer acetate; Interferon beta-1a; Methylprednisolone
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms RESTORE
- Sponsors Biogen
- 19 Sep 2020 Results from RESTORE (n=175) developing model for efficacy of natalizumab extended interval dosing and retrospectively validating Models using data from REFINE, published in the Journal of Clinical Pharmacology
- 12 Oct 2018 Results assessing relationship between Serum neurofilament light (sNfL) dynamics and radiologic disease activity in retrospective analysis performed on a subset of n=65 multiple sclerosis patients, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 15 Sep 2017 Results assessing reversibility of natalizumab-mediated changes in pharmacokinetics/pharmacodynamics using patient data from AFFIRM and RESTORE trials published in the Neurology